BioSpace News Archive

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the launch of Twist Multiplexed Gene Fragments, pools of directly synthesized double-stranded DNA up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications.

May Health announced it has closed a $25 million Series B financing round, co-led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, as well as Avestria Ventures and Kidron Capital Assets LP.

Ensysce Biosciences, Inc. today reported financial and operational results for the first quarter ended March 31, 2024.

The study design and baseline characteristics of FINE-HEART, a new prespecified, exploratory pooled analysis of three Phase III trials with finerenone, were presented as a Late-Breaking Science Session at Heart Failure 2024, a scientific congress of the European Society of Cardiology in Lisbon.

Alpha Tau Medical Ltd. announced today that its first patient with liver cancer metastases has been treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada.

Milestone Scientific Inc. today announced that it will host a conference call at 8:30 AM Eastern Time on Thursday, May 16th, 2024, to discuss the company’s financial results for the first quarter ended March 31, 2024, as well as the company’s corporate progress and other developments.

The Foundation for the National Institutes of Health announces that Love Collins, III, has joined as Vice President of Advancement.

Actinium Pharmaceuticals, Inc. announced that five abstracts have been accepted for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada.

CLEW Medical, a clinical surveillance and predictive analytics company, today announced that its second-generation, AI/machine-learning models for predicting patient deterioration have received 510(k) clearance from the Food & Drug Administration (FDA).

Pheast Therapeutics today announced the first presentation of preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells.